TetraGenetics Expands Collaboration with Top Tier Biotech Partner

BOSTON–(BUSINESS WIRE)–TetraGenetics, a biopharmaceutical company developing novel therapeutics
for autoimmune diseases and pain, announced today a significant
expansion of an existing strategic R&D collaboration with an industry
leading biotech partner.

The new programs, which are non-exclusive, expand the relationship from
the single initial collaboration to now include a total of five drug
discovery programs.

For each program, TetraGenetics is developing unique customized antigens
and screening formulations to support the research and drug discovery
activities. The TetraGenetics materials will be produced using
TetraExpress™ the company’s proprietary platform for recombinant protein

This single agreement now includes total potential payments to
TetraGenetics exceeding $300M in the form of multiple milestone payments.

The accelerated collaboration will launch immediately. All materials are
to be delivered during 2018 to support drug discovery programs in 2018
and 2019.

Doug Kahn, Chairman and CEO of TetraGenetics noted, “Each of these
programs involve membrane protein targets, an area of TetraGenetics
expertise and ideally suited to the capabilities of the TetraExpress™
platform technology. These programs build on TetraGenetics’ prior
successes using the platform for the discovery of drug candidates
targeting membrane proteins.”

About TetraGenetics: TetraGenetics
is an early stage drug discovery company. It uses proprietary technology
(TetraExpress™) to discover large molecule drugs targeting ion channel
membrane proteins associated with many human diseases. The company’s
drug discovery focus is on first-in-class biologics for autoimmune
diseases and pain. For more information, please visit: www.tetragenetics.com.


TetraGenetics, Inc.
Suzanne Gibbons-Neff, 203-858-1325